Science keeps handing the law a mirror. And the law keeps flinching.

The gap between what science can do and what law allows

I think about this every time I read a new headline about gene editing or a wrongful conviction overturned by DNA. The science moves fast. The law moves like it is afraid of the answer. We are living through a moment where two of the most powerful forces in human civilization, biology and jurisprudence, are colliding in ways that will define the next century. Most people are not paying close enough attention.

Consider what is happening right now with CRISPR. An NIH-funded research team has just developed an enhanced CRISPR system small enough to be delivered directly inside the human body, targeting diseases like cancer and ALS. The engineered variant they built improved gene-editing efficiency from under 10% to over 80% across tested targets. That is not incremental progress. That is a leap.

And yet the legal frameworks governing what scientists can actually do with this tool are still largely built on fears from a decade ago. That is unserious.

What Casgevy proved and why regulators almost missed it

Let me give you the clearest proof that science is ahead of the law. Casgevy, the first FDA-approved CRISPR therapy, was cleared in December 2023 for sickle cell disease in patients 12 and older. In the supporting clinical study, 29 of 31 evaluable patients achieved freedom from severe pain crises for at least 12 consecutive months. All treated patients achieved successful engraftment. Zero graft failures.

Sickle cell disease affects roughly 100,000 people in the United States and over 3 million worldwide, with the majority living in Africa. For generations, the only durable treatment was a bone marrow transplant requiring a matched sibling donor, which applies to only about 15% of patients. CRISPR did not just improve on that. It replaced the entire premise.

“By editing certain cells, we decrease pain caused by vaso-occlusive crises and decrease hospitalizations for people with sickle cell disease.”

— Dr. Monica Bhatia, Columbia University Irving Medical Center

The good edge here is real and worth naming plainly: this is genuinely transformative medicine. The science delivered on a promise that felt like science fiction just fifteen years ago. I remember reading about sickle cell as a law student and thinking the disease was simply a life sentence of pain management. It is not anymore.

The price tag is the scandal hiding in plain sight

Now for the bad edge, and it is a serious one. Vertex Pharmaceuticals priced Casgevy at $2.2 million per patient. The competing therapy, Lyfgenia, was priced at $3.1 million. Even if regulators and scientists did everything right, the legal and economic architecture around drug pricing means this cure is effectively inaccessible to most of the people who need it most.

Would you trust a system that invents a cure and then prices it out of reach for the communities most devastated by the disease? Tell me that is fair.

DNA evidence and the law's long, shameful delay

The CRISPR story is about science racing ahead. The DNA exoneration story is about law dragging its feet for decades. The Innocence Project, founded in 1992 by Barry Scheck and Peter Neufeld, has helped exonerate over 375 wrongfully convicted people in the United States through DNA testing alone. Those 375 people collectively served more than 5,600 years in prison for crimes they did not commit.

The misapplication of forensic science contributed to 45 percent of wrongful convictions in the United States proven through DNA evidence. Nearly half. That is not a rounding error. That is a systemic failure dressed up as due process.

The counterpunch argument goes like this: the law is cautious by design, and caution protects the innocent from hasty science. I do not buy that. Caution that keeps an innocent person in prison for twenty years is not a virtue. It is cowardice with a procedural excuse.

Science changed the rules and the law finally had to follow

What gives me genuine hope is that the law does eventually move. Post-conviction DNA testing access laws now exist in all 50 states. States like Michigan and Nevada have passed laws allowing courts to revisit cases where shifts in scientific understanding undermine the original conviction. Kansas now requires uniform protocols for handling DNA database hits that could point to the wrong person being imprisoned.

These reforms did not come from the legal system's generosity. They came because science made the old rules look indefensible.

The same dynamic is now playing out with CRISPR. Researchers at UC San Diego have built a CRISPR tool that spreads through bacterial communities and deletes antibiotic resistance genes, potentially reversing one of the most dangerous public health crises of our era. Projections suggest antibiotic-resistant superbugs could kill more than 10 million people per year by 2050. The science has a plan. Does the law?

The legal framework we need is not the one we have

The somatic versus germline distinction in gene editing law is genuinely smart policy. Somatic editing targets cells in a living person and is not heritable. Germline editing affects embryos and would pass changes to future generations. That line matters enormously, and regulators who hold it firm deserve credit. When He Jiankui edited human embryos in China in 2018 without proper consent or safety data, he was sentenced to three years in prison. That was the right call.

But the legal architecture around access, pricing, and long-term liability for gene therapies is still dangerously underdeveloped. Regulators require 10 to 15 years of post-approval follow-up for CRISPR therapies to catch delayed adverse events. That is responsible science. What is not responsible is having no serious legal mechanism to ensure the people who need these therapies can actually reach them.

Science has earned the right to lead this conversation. The question is whether the law will finally stop treating every breakthrough as a threat to manage and start treating it as a problem to solve.